889 related articles for article (PubMed ID: 26818199)
41. ΔNp63α expression induces loss of cell adhesion in triple-negative breast cancer cells.
Nekulova M; Holcakova J; Gu X; Hrabal V; Galtsidis S; Orzol P; Liu Y; Logotheti S; Zoumpourlis V; Nylander K; Coates PJ; Vojtesek B
BMC Cancer; 2016 Oct; 16(1):782. PubMed ID: 27724925
[TBL] [Abstract][Full Text] [Related]
42. Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.
Yu Z; Dong X; Song M; Xu A; He Q; Li H; Ouyang W; Chouchane L; Ma X
Int J Cancer; 2024 Feb; 154(4):723-737. PubMed ID: 37855385
[TBL] [Abstract][Full Text] [Related]
43. Targeted p53 activation by saRNA suppresses human bladder cancer cells growth and metastasis.
Wang C; Ge Q; Zhang Q; Chen Z; Hu J; Li F; Ye Z
J Exp Clin Cancer Res; 2016 Mar; 35():53. PubMed ID: 27012825
[TBL] [Abstract][Full Text] [Related]
44. The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.
Thies KA; Cole MW; Schafer RE; Spehar JM; Richardson DS; Steck SA; Das M; Lian AW; Ray A; Shakya R; Knoblaugh SE; Timmers CD; Ostrowski MC; Chakravarti A; Sizemore GM; Sizemore ST
Breast Cancer Res; 2021 Jun; 23(1):65. PubMed ID: 34118960
[TBL] [Abstract][Full Text] [Related]
45. Association between Mutation and Expression of
Kim JY; Park K; Jung HH; Lee E; Cho EY; Lee KH; Bae SY; Lee SK; Kim SW; Lee JE; Nam SJ; Ahn JS; Im YH; Park YH
Cancer Res Treat; 2016 Oct; 48(4):1338-1350. PubMed ID: 26910472
[TBL] [Abstract][Full Text] [Related]
46. RB1 deficiency in triple-negative breast cancer induces mitochondrial protein translation.
Jones RA; Robinson TJ; Liu JC; Shrestha M; Voisin V; Ju Y; Chung PE; Pellecchia G; Fell VL; Bae S; Muthuswamy L; Datti A; Egan SE; Jiang Z; Leone G; Bader GD; Schimmer A; Zacksenhaus E
J Clin Invest; 2016 Oct; 126(10):3739-3757. PubMed ID: 27571409
[TBL] [Abstract][Full Text] [Related]
47. SOCS3-mediated regulation of inflammatory cytokines in PTEN and p53 inactivated triple negative breast cancer model.
Kim G; Ouzounova M; Quraishi AA; Davis A; Tawakkol N; Clouthier SG; Malik F; Paulson AK; D'Angelo RC; Korkaya S; Baker TL; Esen ES; Prat A; Liu S; Kleer CG; Thomas DG; Wicha MS; Korkaya H
Oncogene; 2015 Feb; 34(6):671-80. PubMed ID: 24531711
[TBL] [Abstract][Full Text] [Related]
48. Inhibition of iNOS as a novel effective targeted therapy against triple-negative breast cancer.
Granados-Principal S; Liu Y; Guevara ML; Blanco E; Choi DS; Qian W; Patel T; Rodriguez AA; Cusimano J; Weiss HL; Zhao H; Landis MD; Dave B; Gross SS; Chang JC
Breast Cancer Res; 2015 Feb; 17(1):25. PubMed ID: 25849745
[TBL] [Abstract][Full Text] [Related]
49. Deptor enhances triple-negative breast cancer metastasis and chemoresistance through coupling to survivin expression.
Parvani JG; Davuluri G; Wendt MK; Espinosa C; Tian M; Danielpour D; Sossey-Alaoui K; Schiemann WP
Neoplasia; 2015 Mar; 17(3):317-28. PubMed ID: 25810016
[TBL] [Abstract][Full Text] [Related]
50. Identifying biomarkers of breast cancer micrometastatic disease in bone marrow using a patient-derived xenograft mouse model.
Pillai SG; Li S; Siddappa CM; Ellis MJ; Watson MA; Aft R
Breast Cancer Res; 2018 Jan; 20(1):2. PubMed ID: 29291741
[TBL] [Abstract][Full Text] [Related]
51. A CTC-Cluster-Specific Signature Derived from OMICS Analysis of Patient-Derived Xenograft Tumors Predicts Outcomes in Basal-Like Breast Cancer.
Thangavel H; De Angelis C; Vasaikar S; Bhat R; Jolly MK; Nagi C; Creighton CJ; Chen F; Dobrolecki LE; George JT; Kumar T; Abdulkareem NM; Mao S; Nardone A; Rimawi M; Osborne CK; Lewis MT; Levine H; Zhang B; Schiff R; Giuliano M; Trivedi MV
J Clin Med; 2019 Oct; 8(11):. PubMed ID: 31652963
[TBL] [Abstract][Full Text] [Related]
52. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
53. Stimulation of triple negative breast cancer cell migration and metastases formation is prevented by chloroquine in a pre-irradiated mouse model.
Bouchard G; Therriault H; Geha S; Bérubé-Lauzière Y; Bujold R; Saucier C; Paquette B
BMC Cancer; 2016 Jun; 16():361. PubMed ID: 27282478
[TBL] [Abstract][Full Text] [Related]
54. Integration of whole-genome sequencing and functional screening identifies a prognostic signature for lung metastasis in triple-negative breast cancer.
Xie G; Yang H; Ma D; Sun Y; Chen H; Hu X; Jiang YZ; Shao ZM
Int J Cancer; 2019 Nov; 145(10):2850-2860. PubMed ID: 30977117
[TBL] [Abstract][Full Text] [Related]
55. Diallyl disulfide inhibits growth and metastatic potential of human triple-negative breast cancer cells through inactivation of the β-catenin signaling pathway.
Huang J; Yang B; Xiang T; Peng W; Qiu Z; Wan J; Zhang L; Li H; Li H; Ren G
Mol Nutr Food Res; 2015 Jun; 59(6):1063-75. PubMed ID: 25755089
[TBL] [Abstract][Full Text] [Related]
56. In Vivo Isolation of a Highly-aggressive Variant of Triple-negative Human Breast Cancer MDA-MB-231 Using Serial Orthotopic Transplantation.
Yano S; Takehara K; Miwa S; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
Anticancer Res; 2016 Aug; 36(8):3817-20. PubMed ID: 27466482
[TBL] [Abstract][Full Text] [Related]
57. Cancer Testis Antigen Promotes Triple Negative Breast Cancer Metastasis and is Traceable in the Circulating Extracellular Vesicles.
Kannan A; Philley JV; Hertweck KL; Ndetan H; Singh KP; Sivakumar S; Wells RB; Vadlamudi RK; Dasgupta S
Sci Rep; 2019 Aug; 9(1):11632. PubMed ID: 31406142
[TBL] [Abstract][Full Text] [Related]
58. Mutant p53 accumulation in human breast cancer is not an intrinsic property or dependent on structural or functional disruption but is regulated by exogenous stress and receptor status.
Bouchalova P; Nenutil R; Muller P; Hrstka R; Appleyard MV; Murray K; Jordan LB; Purdie CA; Quinlan P; Thompson AM; Vojtesek B; Coates PJ
J Pathol; 2014 Jul; 233(3):238-46. PubMed ID: 24687952
[TBL] [Abstract][Full Text] [Related]
59. Establishment of an orthotopic patient-derived xenograft mouse model using uveal melanoma hepatic metastasis.
Kageyama K; Ohara M; Saito K; Ozaki S; Terai M; Mastrangelo MJ; Fortina P; Aplin AE; Sato T
J Transl Med; 2017 Jun; 15(1):145. PubMed ID: 28645290
[TBL] [Abstract][Full Text] [Related]
60. In Vivo Selection of Intermediately- and Highly-Malignant Variants of Triple-negative Breast Cancer in Orthotopic Nude Mouse Models.
Yano S; Takehara K; Kishimoto H; Tazawa H; Urata Y; Kagawa S; Bouvet M; Fujiwara T; Hoffman RM
Anticancer Res; 2016 Dec; 36(12):6273-6277. PubMed ID: 27919946
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
